3 ms·

>> Every biotech with the capability is already building out a pipeline to produce a generic or their own GLP drug. Just speculation or got a link?

0cf8612b2e1e 2y ago
Speculation, but below is a search hit about companies with public GLP1 programs in the works. These would be companies hoping to make an improved drug (oral or better weight loss/tolerability properties). I am sure there are others with less visibility. Generics development is probably more stealthy. I think technically you are not allowed to use/test a competitor compound, but I am sure everyone does it. https://www.forbes.com/sites/roberthart/2024/07/16/ozempic-and-wegovy-rivals-here-are-the-companies-working-on-competitor-weight-loss-drugs/ https://www.forbes.com/sites/roberthart/2024/07/16/ozempic-a...
hnburnsy 2y ago
>Just speculation or got a link? The pipeline is bursting and many are more effective (longer lasting\better form factor). I think I count 18 from the main chart in this research paper... https://www.nature.com/articles/s41366-024-01473-y https://www.nature.com/articles/s41366-024-01473-y From the conclusion... >A new era for obesity treatment has commenced where pharmacotherapy with combinations of entero-pancreatic hormones approach the WL efficacy of bariatric surgery. Tirzepatide is the first dual agonist which has been approved for chronic weight management, but numerous other dual and/or triple agonists (cagrisema, retatrutide, mazdutide and survodutide) are also in phase 3 trials as potential treatments for obesity and its metabolic complications. Moreover, oral GLP-1 RA are also under development and will provide an alternative option. >The plethora of efficacious obesity pharmacotherapies with different mechanisms of action will allow tailored treatment plans based on individual’s preference, comorbidities and treatment response. A percentage of people will not be able to tolerate the new pharmacotherapies or achieve the individualised goals and others may not have long-term access to these treatments. Combining different treatment modalities (including lifestyle interventions, pharmacotherapies and bariatric surgery) may support people to achieve individualised long-term goals, maximise health benefits and improve quality of life.

0cf8612b2e1e 2y ago

Speculation, but below is a search hit about companies with public GLP1 programs in the works. These would be companies hoping to make an improved drug (oral or better weight loss/tolerability properties). I am sure there are others with less visibility. Generics development is probably more stealthy. I think technically you are not allowed to use/test a competitor compound, but I am sure everyone does it. https://www.forbes.com/sites/roberthart/2024/07/16/ozempic-and-wegovy-rivals-here-are-the-companies-working-on-competitor-weight-loss-drugs/ https://www.forbes.com/sites/roberthart/2024/07/16/ozempic-a...

hnburnsy 2y ago

>Just speculation or got a link? The pipeline is bursting and many are more effective (longer lasting\better form factor). I think I count 18 from the main chart in this research paper... https://www.nature.com/articles/s41366-024-01473-y https://www.nature.com/articles/s41366-024-01473-y From the conclusion... >A new era for obesity treatment has commenced where pharmacotherapy with combinations of entero-pancreatic hormones approach the WL efficacy of bariatric surgery. Tirzepatide is the first dual agonist which has been approved for chronic weight management, but numerous other dual and/or triple agonists (cagrisema, retatrutide, mazdutide and survodutide) are also in phase 3 trials as potential treatments for obesity and its metabolic complications. Moreover, oral GLP-1 RA are also under development and will provide an alternative option. >The plethora of efficacious obesity pharmacotherapies with different mechanisms of action will allow tailored treatment plans based on individual’s preference, comorbidities and treatment response. A percentage of people will not be able to tolerate the new pharmacotherapies or achieve the individualised goals and others may not have long-term access to these treatments. Combining different treatment modalities (including lifestyle interventions, pharmacotherapies and bariatric surgery) may support people to achieve individualised long-term goals, maximise health benefits and improve quality of life.